Anti-PD-1 With or Without Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

被引：0
|
作者：
Teng, F. [1 ]
Wang, P. [2 ,3 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[3] Shandong Univ, Shandong Canc Hosp & Inst, Cheeloo Coll Med, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2943
引用
收藏
页码：E455 / E456
页数：2
相关论文
共 50 条
  • [21] The Efficacy and Safety of Anti-PD-1 in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Systematic Review
    Di, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1917 - S1917
  • [22] Predictive biomarker of response to anti-PD-1 treatment in non-small cell lung cancer patients.
    Zheng, Xuan
    Hu, Yi
    Ma, Junxun
    Zhang, Fan
    Sun, Danyang
    Li, Lingling
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [23] Predictive biomarkers of response to anti-PD-1 treatment in non-small cell lung cancer patients.
    Zheng, Xuan
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Prognostic Nomogram for Advanced Non-Small Cell Lung Cancer Patients Treated With Anti-PD-1 Inhibitors
    Chai, R.
    Fan, Y.
    Zhao, J.
    He, F.
    Han, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S254 - S255
  • [25] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (12) : 1355 - 1363
  • [26] Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy
    Li, Mengqian
    Gan, Lu
    Song, Andrew
    Xue, Jianxin
    Lu, You
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (02): : 323 - 330
  • [27] A Pilot Study of Anti-PD-1 Antibody SHR-1210 with Hypofractionated Radiation Therapy in Patients with Oligometastatic Non-Small Cell Lung Cancer (NSCLC)
    Teng, F.
    Xing, L.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E535 - E535
  • [28] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
  • [29] Predictive immunological markers of anti-PD-1/PD-L1 therapy efficacy in non-small cell lung cancer
    Musaelyan, A. A.
    Lapin, S. V.
    Urtenova, M. A.
    Chistyakov, I. V.
    Nazarov, V. D.
    Akopov, A. L.
    Orlov, S. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S1382 - S1382
  • [30] Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
    Shah, Shalin
    Wood, Kevin
    Brisson, Ryan
    Karrison, Theodore
    Hensing, Thomas
    Luke, Jason J.
    Patel, Jyoti D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S310 - S310
12345